Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Renibus Therapeutics Inc.
Headquarters: Southlake, TX, United States of America
Website: https://www.renibus.com/
Year Founded: 2015
Status: Private
BioCentury | Mar 23, 2024
Management Tracks
Braunstein retiring as Idorsia CMO
Plus: Lys names Vounatsos chair and updates from Theolytics, BeiGene, Renibus and MaaT
BioCentury | Jul 18, 2023
Finance
July 18 Quick Takes: Pfizer, Flagship to launch up to 10 single-asset programs
Plus: J&J joins the IRA litigation club and updates from Novartis, Neurogene and Renibus
BioCentury | Dec 14, 2022
Management Tracks
Quanta names Exelixis alum Faoro as CMO
Plus: Abingworth adds Joy Ghosh as managing director and Renibus hires Ramdas as SVP
BioCentury | Jun 17, 2022
Product Development
June 16 Quick Takes: BioInvent gets $25M in mAb discovery deal with Exelixis
Plus Biogen returns Karyopharm ALS asset and updates from Akero, Rhythm and more
BioCentury | Jun 3, 2022
Management Tracks
AbbVie’s Severino joins Flagship’s Tessera as CEO
Plus new CFO, CMO at Renibus, and updates from Bayer, Gilead, Shionogi and more
BioCentury | Feb 17, 2022
Management Tracks
New leadership for Merck’s human health business
Plus new CEOs at Renibus and Indapta, updates from Milestone, Briacell and more
BioCentury | Oct 13, 2020
Product Development
Data Bytes: coronavirus-targeted small molecules
The SARS-CoV-2 protease is the top target for small molecule COVID-19 candidates developed with a coronavirus infection as their original indication, of which only a handful have entered the
Items per page:
1 - 7 of 7